Danaher (NYSE:DHR) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Danaher (NYSE:DHR) from a hold rating to a buy rating in a research report released on Wednesday.

Several other research firms also recently commented on DHR. UBS Group reduced their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Barclays decreased their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a report on Thursday, October 31st. Stephens reiterated an “overweight” rating and set a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. Finally, TD Cowen raised their price target on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Stock Up 1.0 %

Shares of NYSE:DHR opened at $238.90 on Wednesday. The firm has a market capitalization of $172.55 billion, a PE ratio of 45.59, a price-to-earnings-growth ratio of 4.37 and a beta of 0.85. Danaher has a 52-week low of $215.68 and a 52-week high of $281.70. The firm has a fifty day moving average of $256.00 and a 200 day moving average of $259.66. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the company earned $2.02 earnings per share. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year. As a group, research analysts anticipate that Danaher will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher’s payout ratio is 20.61%.

Institutional Investors Weigh In On Danaher

Several institutional investors and hedge funds have recently modified their holdings of DHR. nVerses Capital LLC purchased a new stake in Danaher in the 2nd quarter worth $25,000. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher in the second quarter worth about $25,000. Teachers Insurance & Annuity Association of America purchased a new stake in shares of Danaher in the third quarter worth about $39,000. MidAtlantic Capital Management Inc. bought a new position in Danaher during the third quarter valued at approximately $40,000. Finally, FSA Wealth Management LLC purchased a new position in Danaher during the 3rd quarter valued at approximately $50,000. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.